NO20054140L - Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse - Google Patents
Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelseInfo
- Publication number
- NO20054140L NO20054140L NO20054140A NO20054140A NO20054140L NO 20054140 L NO20054140 L NO 20054140L NO 20054140 A NO20054140 A NO 20054140A NO 20054140 A NO20054140 A NO 20054140A NO 20054140 L NO20054140 L NO 20054140L
- Authority
- NO
- Norway
- Prior art keywords
- medicament
- ring
- compound
- optionally substituted
- dihydrospiro
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 title abstract 2
- 150000008318 pyrimidones Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290569A EP1454909B1 (en) | 2003-03-07 | 2003-03-07 | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
| PCT/EP2004/003051 WO2004078760A1 (en) | 2003-03-07 | 2004-03-05 | SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054140D0 NO20054140D0 (no) | 2005-09-06 |
| NO20054140L true NO20054140L (no) | 2005-12-02 |
Family
ID=32799103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054140A NO20054140L (no) | 2003-03-07 | 2005-09-06 | Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7294632B2 (enExample) |
| EP (2) | EP1454909B1 (enExample) |
| JP (1) | JP4639182B2 (enExample) |
| KR (1) | KR101069984B1 (enExample) |
| CN (1) | CN100463908C (enExample) |
| AR (1) | AR043485A1 (enExample) |
| AT (1) | ATE469153T1 (enExample) |
| AU (1) | AU2004218250B2 (enExample) |
| BR (1) | BRPI0408189A (enExample) |
| CA (1) | CA2516937C (enExample) |
| CY (1) | CY1111057T1 (enExample) |
| DE (1) | DE602004027354D1 (enExample) |
| DK (1) | DK1603915T3 (enExample) |
| EA (1) | EA008172B1 (enExample) |
| ES (1) | ES2346311T3 (enExample) |
| IL (1) | IL170461A (enExample) |
| MX (1) | MXPA05009574A (enExample) |
| NO (1) | NO20054140L (enExample) |
| NZ (1) | NZ542135A (enExample) |
| PL (1) | PL1603915T3 (enExample) |
| PT (1) | PT1603915E (enExample) |
| SI (1) | SI1603915T1 (enExample) |
| TW (1) | TWI320785B (enExample) |
| WO (1) | WO2004078760A1 (enExample) |
| ZA (1) | ZA200507107B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080025079A (ko) | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP1992620A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992625A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone compounds |
| EP1992621A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
| EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
| EP2138498A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| SI2448940T1 (sl) | 2009-07-02 | 2014-10-30 | Sanofi | Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba |
| WO2012085244A1 (fr) | 2010-12-23 | 2012-06-28 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812636A1 (fr) * | 2000-08-02 | 2002-02-08 | Novapharme | Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones |
| EP1184385A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| ATE269333T1 (de) * | 2000-09-01 | 2004-07-15 | Sanofi Synthelabo | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate |
| EP1184383A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives |
| EP1295884A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives |
| KR100868840B1 (ko) * | 2001-09-21 | 2008-11-14 | 사노피-아벤티스 | 신경퇴행성 장애를 위한 치환된2-피리미디닐-6,7,8,9-테트라히드로피리미도[1,2-ａ]피리미딘-4-온 및7-피리미디닐-2,3-디히드로이미다조[1,2-ａ]피리미딘-5(1ｈ)온 유도체 |
| DE60227718D1 (de) * | 2001-09-21 | 2008-08-28 | Sanofi Aventis | Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen |
| EP1295885A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives |
-
2003
- 2003-03-07 EP EP03290569A patent/EP1454909B1/en not_active Expired - Lifetime
-
2004
- 2004-03-05 DE DE602004027354T patent/DE602004027354D1/de not_active Expired - Lifetime
- 2004-03-05 CN CNB2004800109973A patent/CN100463908C/zh not_active Expired - Fee Related
- 2004-03-05 TW TW093105914A patent/TWI320785B/zh not_active IP Right Cessation
- 2004-03-05 DK DK04717643.3T patent/DK1603915T3/da active
- 2004-03-05 AT AT04717643T patent/ATE469153T1/de active
- 2004-03-05 WO PCT/EP2004/003051 patent/WO2004078760A1/en not_active Ceased
- 2004-03-05 PL PL04717643T patent/PL1603915T3/pl unknown
- 2004-03-05 CA CA2516937A patent/CA2516937C/en not_active Expired - Fee Related
- 2004-03-05 ZA ZA200507107A patent/ZA200507107B/en unknown
- 2004-03-05 AU AU2004218250A patent/AU2004218250B2/en not_active Ceased
- 2004-03-05 BR BRPI0408189-7A patent/BRPI0408189A/pt not_active IP Right Cessation
- 2004-03-05 AR ARP040100694A patent/AR043485A1/es not_active Application Discontinuation
- 2004-03-05 PT PT04717643T patent/PT1603915E/pt unknown
- 2004-03-05 EP EP04717643A patent/EP1603915B1/en not_active Expired - Lifetime
- 2004-03-05 JP JP2006504813A patent/JP4639182B2/ja not_active Expired - Fee Related
- 2004-03-05 NZ NZ542135A patent/NZ542135A/en not_active IP Right Cessation
- 2004-03-05 MX MXPA05009574A patent/MXPA05009574A/es active IP Right Grant
- 2004-03-05 ES ES04717643T patent/ES2346311T3/es not_active Expired - Lifetime
- 2004-03-05 SI SI200431465T patent/SI1603915T1/sl unknown
- 2004-03-05 EA EA200501241A patent/EA008172B1/ru not_active IP Right Cessation
-
2005
- 2005-08-23 IL IL170461A patent/IL170461A/en not_active IP Right Cessation
- 2005-09-06 KR KR1020057016622A patent/KR101069984B1/ko not_active Expired - Fee Related
- 2005-09-06 NO NO20054140A patent/NO20054140L/no not_active Application Discontinuation
- 2005-09-07 US US11/220,999 patent/US7294632B2/en not_active Expired - Fee Related
-
2007
- 2007-10-02 US US11/866,142 patent/US7507743B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 CY CY20101100761T patent/CY1111057T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054140L (no) | Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse | |
| NO20054330L (no) | 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| NO20054331L (no) | Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| NO20063187L (no) | Substituerte 8'-pyri(mi)dinyl-dihydrospiro-[cykloalkylamin]-pyrimido[1,2-a]pyrimidin-6-on-derivater | |
| NO20064456L (no) | Thiadiazolidinoner som GSK-3 inhibitorer | |
| WO2008056266A3 (en) | Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives | |
| NO20092373L (no) | Substituerte heteroarylpyridopyrimidonderivater | |
| MX2009006947A (es) | Derivados de pirimidona 6-heterociclica 2-sustituida. | |
| WO2007057790A3 (en) | Substituted bicyclic pyrimidone derivatives | |
| NO20090749L (no) | Arylaminoaryl-alkyl-substituerte imidazolidin-2,4-dioner, fremgangsmate for fremstilling derav, medikamenter inneholdende forbindelsene og deres anvendelse | |
| NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| MX2010008363A (es) | Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta. | |
| WO2009121535A3 (en) | Antiproliferative compounds and therapeutic uses thereof | |
| BRPI0515851A (pt) | composto de pirimidona | |
| SG161217A1 (en) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | |
| DE60335404D1 (de) | Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges | |
| MX2010002765A (es) | Derivado de 6-pirimidinil-pirimid-4-ona. | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| ZA202405279B (en) | Heteroaryl derivative and use thereof | |
| ATE389654T1 (de) | Cycloalkyl substituierte 7-amino-4-chinolon-3- carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| NO20054141L (no) | 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse | |
| ATE448214T1 (de) | Neue 3-phenylpropionsäurederivate und ihre verwendung als ppar-gamma-rezeptorliganden | |
| ATE480535T1 (de) | Neue pyridoncarboxylsäurederivative oder salze daraus | |
| TH106080A (th) | อนุพันธ์ของ 2-ที่ถูกแทนที่-6-เฮเทอโรไซคลิค ไพริมิโดน | |
| TH82134B (th) | อนุพันธ์ซับสทิทิวเทค 2-(ไอแอซา-ไบไซโคล-แอลคิล)-ไพริมิโดน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |